Multicenter prospective phase ii trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer

Journal of Clinical Oncology

Volumn 36, Issue 19, 2018, Pages 1949-1956

  Iyer, Gopa ^a,b   Balar, Arjun V ^c   Milowsky, Matthew I ^d   Bochner, Bernard H ^a,b   Dalbagni, Guido ^a,b   Machele Donat, S ^a,b   Herr, Harry W ^a,b   Huang, William C ^c   Taneja, Samir S ^c   Woods, Michael ^d   Ostrovnaya, Irina ^a   Al Ahmadie, Hikmat ^a,b   Arcila, Maria E ^a   Riches, Jamie C ^a   Meier, Andreas ^a   Bourque, Caitlin ^a   Shady, Maha ^a   Won, Helen ^a   Rose, Tracy L ^d   Kim, William Y ^d   Kania, Brooke E ^a   Boyd, Mariel E ^a   Cipolla, Catharine K ^a   Regazzi, Ashley M ^a   Delbeau, Daniela ^c   McCoy, Asia S ^a   Vargas, Hebert Alberto ^a   Berger, Michael F ^a   Solit, David B ^a,b   Rosenberg, Jonathan E ^a   Bajorin, Dean F ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; GEMCITABINE; TELOMERASE REVERSE TRANSCRIPTASE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FILGRASTIM; MACROGOL; PEGFILGRASTIM;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONSTIPATION; CYSTECTOMY; CYSTITIS; DEHYDRATION; DIARRHEA; DNA DAMAGE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LYMPH NODE METASTASIS; MACULOPAPULAR RASH; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NAUSEA; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TINNITUS; URINARY FREQUENCY; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BLADDER TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; NEOADJUVANT THERAPY; PATHOLOGY; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FILGRASTIM; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 85049402912     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.75.0158     Document Type: Article

References (38)

1. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
2. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11:408-414, 1993
3. Sternberg CN, de Mulder PH, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638-2646, 2001
4. Choueiri TK, Jacobus S, Bellmunt J, et al: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, ra-diologic, and biomarker correlates. J Clin Oncol 32: 1889-1894, 2014
5. Plimack ER, Hoffman-Censits JH, Viterbo R, et al: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 32:1895-1901, 2014
6. Dash A, Pettus JA IV, Herr HW, et al: A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience. Cancer 113:2471-2477, 2008
7. Plimack ER, Hoffman-Censits JH, Kutikov A, et al: Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study. J Clin Oncol 32:5s, 2014 (suppl; abstr 4513)
8. David KA, Milowsky MI, Ritchey J, et al: Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 178:451-454, 2007
9. Sun JM, Sung JY, Park SH, et al: ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer 12:187, 2012
10. Van Allen EM, Mouw KW, Kim P, et al: Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140-1153, 2014
11. Plimack ER, Dunbrack RL, Brennan TA, et al: Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68:959-967, 2015
12. Stadler WM, Lerner SP, Groshen S, et al: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 29:3443-3449, 2011
13. Bamias A, Dafni U, Karadimou A, et al: Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/ cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: A Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol 24: 1011-1017, 2013
14. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
15. Sternberg CN, Calabrò F, Pizzocaro G, et al: Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92:2993-2998, 2001
16. Cheng DT, Mitchell TN, Zehir A, et al: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17:251-264, 2015
17. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
18. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 29:2171-2177, 2011
19. Chae YK, Anker JF, Carneiro BA, et al: Genomic landscape of DNA repair genes in cancer. Oncotarget 7:23312-23321, 2016
20. Loeb LA: A mutator phenotype in cancer. Cancer Res 61:3230-3239, 2001
21. Tully CM BB, Dalbagni G, Zabor EC, et al: Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. J Clin Oncol 32, 2014 (suppl; abstr 355)
22. Ciccolini J, Serdjebi C, Peters GJ, et al: Phar-macokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: An EORTC-PAMM perspective. Cancer Chemother Pharmacol 78: 1-12, 2016
23. Peters GJ, Clavel M, Noordhuis P, et al: Clinical phase I and pharmacology study of gemcitabine (29, 29-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother 19:212-221, 2007
24. Moore RA, Adel N, Riedel E, et al: High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 29:3466-3473, 2011
25. Helleday T, Eshtad S, Nik-Zainal S: Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 15:585-598, 2014
26. Kim J, Mouw KW, Polak P, et al: Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 48: 600-606, 2016
27. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322, 2014
28. Peng G, Chun-Jen Lin C, Mo W, et al: Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2014
29. Boyd J, Sonoda Y, Federici MG, et al: Clini-copathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
30. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
31. Golan T, Kanji ZS, Epelbaum R, et al: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111: 1132-1138, 2014
32. Garcia-Aguilar J, Renfro LA, Chow OS, et al: Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): Results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 16:1537-1546, 2015
33. Lefebvre JL, Pointreau Y, Rolland F, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol 31:853-859, 2013
34. Henningsohn L, Steven K, Kallestrup EB, et al: Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 168:168-174, discussion 174-175, 2002
35. Efstathiou JA, Spiegel DY, Shipley WU, et al: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 61: 705-711, 2012
36. Herr HW, Bajorin DF, Scher HI: Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol 16:1298-1301, 1998
37. Sternberg CN, Pansadoro V, Calabrò F, et al: Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97: 1644-1652, 2003
38. Meyer A, Ghandour R, Bergman A, et al: The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J Urol 192:696-701, 2014